In general, early-stage diseases in the oral cavity, laryngeal, hypopharyngeal, and p16- negative and p16-positive oropharyngeal cancer are treated with a single-modality approach, radiotherapy (RT), or conservative surgery. Here, CDKN2A is linked to oropharynx cancer.